On Tuesday 5th December, the Oxford early cancer detection community gathered at the Mathematical Institute in Oxford to hear some highlights from OxCODE\u2019s research in the past year and to discuss ideas for future projects.
To celebrate the launch of the UK\u2019s first CRUK clinical trials unit dedicated to cancer precision prevention in Oxford, we held a research symposium that highlighted the spectra of Cancer Precision Prevention clinical programmes across the UK.
The Nuffield Department of Primary Care Health Sciences wins an NIHR award for a new HealthTech Research Centre (HRC) to explore innovative Health Technology to enhance community and primary care.
SerenOx Africa, led by Professor Anna Schuh, aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility also aims to provide early cancer detection for high-risk patients.
An agreement between Satisfai Health Inc and the University of Oxford will progress the automated assessment of Barrett\u2019s oesophagus with the aim of determining patients most at risk of developing oesophageal cancer.
Congratulations to James Chettle, Masato Inoue and Eoghan Mulholland who have been awarded OxCODE funds to attend this year\u2019s Early Detection of Cancer conference in London.
Oxford\u2019s first precision prevention cancer trial in people with Li Fraumeni Syndrome will also shed light on the mechanisms of cancer development in the general population
A study led by the Mead Group has demonstrated a previously unknown effect of chronic inflammation on TP53-mutant blood stem cells, shedding light on the progression of leukaemia.
Congratulations to James McCullagh, Monica Olcina, Bethan Psaila, and their collaborators who have been awarded funding in the fourth round of the OxCODE Funding Scheme.
A team of researchers led by Professor Julia Hippisley-Cox have developed a new model that reliably predicts a woman's likelihood of developing and then dying of breast cancer within a decade.
Blood Cancer UK and Cancer Research UK recognise the need and impact of artificial intelligence approaches developed by Professor Daniel Royston and Professor Jens Rittscher for early detection and assessment of these blood cancers.
In a pan-cancer analysis spanning 24 different cancer types, researchers shed light on the relationship between SETD2, DNA methylation and cancer development.
The National Institute for Health and Care Research (NIHR) has announced a major investment in its Policy Research Units (PRUs). Researchers in the Nuffield Department of Primary Care Health Sciences at Oxford will play a key role in a new Unit focusing on the early detection of cancer.
Oxford researchers have been given a \u00a31 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
David Hunter, Richard Doll Professor of Epidemiology and Medicine at Oxford Population Health and OxCODE Associate Director, has been appointed as a Companion of the Order of Australia in the Australian King\u2019s Birthday Honours List.
An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.
![\"Pathology](\"https://www.oxcode.ox.ac.uk/news/challenges-for-colorectal-cancer-risk-stratification-in-people-with-ibd-using-histology/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n